Neuroendocrine effects of setoperone: a new neuroleptic drug.
Setoperone (R 52245), a serotonin S2 and dopamine D2 receptor blocker, was tested on eight healthy male volunteers, receiving 5 or 40 mg orally, in order to assess the modifications of plasma prolactin levels, as an index of receptor blocking activity. Both doses significantly increased plasma levels, confirming the dopamine blocking activity. In vitro and in vivo studies have shown serotonin S2 receptor blockade and lysergic acid diethylamide antagonist activity. Setoperone is proposed as a possible new neuroleptic drug.
D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000494:pharmacology*; D018492:Dopamine Antagonists; D006801:Humans; D008297:Male; D011388:Prolactin / Q000097:blood*; D011744:Pyrimidinones / Q000494:pharmacology*; D011985:Receptors, Serotonin / Q000378:metabolism
D014150:Antipsychotic Agents; D018492:Dopamine Antagonists; D011744:Pyrimidinones; D011985:Receptors, Serotonin; D011388:Prolactin; C045359:setoperone